<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl0015">
 <label>Table 3</label>
 <caption>
  <p>Vaccine developments by using Non-Replicating Viral Vector platform for COVID-19 according to the WHO as of April 20, 2020 (adapted from (20).</p>
 </caption>
 <alt-text id="at3">Table 3</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="left">Platform</th>
    <th align="left">Type of candidate vaccine</th>
    <th align="left">developer</th>
    <th align="left">stage of clinical evaluation</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left">Non-replicating Viral Vector</td>
    <td align="left">Ad5 Vector</td>
    <td align="left">CanSino Biological Inc. and Beijing Institute of Biotechnology</td>
    <td align="left">Phase 2
     <break/>ChiCTR2000031781
     <break/>Phase 1
     <break/>ChiCTR2000030906
    </td>
   </tr>
   <tr>
    <td/>
    <td align="left">Modified Vaccina Ankara (MVA) encoded VLP</td>
    <td align="left">GeoVax/BravoVax</td>
    <td/>
   </tr>
   <tr>
    <td/>
    <td align="left">Ad26 (alone or with MVA boost)</td>
    <td align="left">Janssen Pharmaceutical Companies</td>
    <td align="left">Pre-Clinical</td>
   </tr>
   <tr>
    <td/>
    <td align="left">ChAdOx1</td>
    <td align="left">University of Oxford</td>
    <td align="left">Phase 1/2
     <break/>NCT04324606
    </td>
   </tr>
   <tr>
    <td/>
    <td align="left">Ad-based Naso VAX expressing SARS2-CoV spike protein</td>
    <td align="left">Altimmune</td>
    <td align="left">Pre-clinical</td>
   </tr>
   <tr>
    <td/>
    <td align="left">Ad5 S (GREVAXâ„¢)</td>
    <td align="left">Greffex</td>
    <td align="left">Pre-clinical</td>
   </tr>
   <tr>
    <td/>
    <td align="left">Oral Vaccine platform</td>
    <td align="left">Vaxart</td>
    <td align="left">Pre-clinical</td>
   </tr>
   <tr>
    <td align="left">Replicating Viral</td>
    <td align="left">Full-length Spike or S1
     <break/>Vector used: ChAd or (Modified Vaccina Ankara) MVA
    </td>
    <td align="left">Zydus Cadila
     <break/>Institut Pasteur/Themis
     <break/>Tonix Pharma/Southern Research
    </td>
    <td align="left">Phase I
     <break/>(NCT03399578,
     <break/>NCT03615911)
    </td>
   </tr>
   <tr>
    <td align="left">Replicating Viral Vector</td>
    <td align="left">Measles Vector</td>
    <td align="left">Zydus Cadila</td>
    <td align="left">Pre-clinical</td>
   </tr>
   <tr>
    <td/>
    <td align="left">Measles Vector</td>
    <td align="left">Institute Pasteur/ Themis/ Univ. of Pittsburg Center for Vaccine Research</td>
    <td align="left">Pre-clinical</td>
   </tr>
   <tr>
    <td/>
    <td align="left">Horse pox vector expressing S protein</td>
    <td align="left">Tonix Pharma/Southern Research</td>
    <td align="left">Pre-clinical</td>
   </tr>
   <tr>
    <td/>
    <td align="left">dendritic cells modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins; administered with antigen- specific CTLs</td>
    <td align="left">Shenzhen
     <break/>Geno- Immune
     <break/>Medical Institute
    </td>
    <td align="left">Phase I
     <break/>(NCT04276896)
    </td>
   </tr>
   <tr>
    <td/>
    <td align="left">artificial antigen- presenting cells modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins</td>
    <td align="left">Shenzhen
     <break/>Geno- Immune
     <break/>Medical Institute
    </td>
    <td align="left">Phase I
     <break/>(NCT04299724)
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
